29121-25-3

Basic information

• Product Name: ethyl 2-(3-bromo-4-hydroxyphenyl)acetate
• Synonyms: ethyl 2-(3-bromo-4-hydroxyphenyl)acetate
• CAS NO: 29121-25-3
• Molecular Formula: C₁₀H₁₁BrO₃
• Molecular Weight: 259.09654
• Mol File: 29121-25-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 2-(3-bromo-4-hydroxyphenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(3-bromo-4-hydroxyphenyl)acetate(29121-25-3)
• EPA Substance Registry System: ethyl 2-(3-bromo-4-hydroxyphenyl)acetate(29121-25-3)

Safety Data

• Hazardous Substances Data: 29121-25-3(Hazardous Substances Data)

Upstream product

• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 
• 156-38-7 4-hydroxyphenylacetate 
• 64-17-5 ethanol 
• 38692-80-7 2-(3-bromo-4-hydroxyphenyl)acetic acid 

Downstream Products

• 1207542-34-4 [3-Bromo-4-(3-chloro-5-cyano-phenoxy)-phenyl]-acetic acid ethyl ester 
• 1168133-68-3 ethyl 2-(3-bromo-5-chloro-4-hydroxyphenyl)acetate 
• 1168133-69-4 ethyl 2-(3-bromo-5-chloro-4-(cyclopropylmethoxy)phenyl)acetate 
• 1168111-82-7 2-(3-(benzo[c][1,2,5]thiadiazol-5-yl)-5-chloro-4-(cyclopropylmethoxy)phenyl)-4-methylpentanoic acid 
• 1168134-93-7 ethyl 2-(3-(benzo[c][1,2,5]thiadiazol-5-yl)-5-chloro-4-(cyclopropylmethoxy)phenyl)-4-methylpentanoate 
• 1168111-72-5 2-(3-(benzo[c][1,2,5]oxadiazol-5-yl)-5-chloro-4-(cyclopropylmethoxy)phenyl)-4-methylpentanoic acid 
• 1168134-92-6 ethyl 2-(3-(benzo[c][1,2,5]oxadiazol-5-yl)-5-chloro-4-(cyclopropylmethoxy)phenyl)-4-methylpentanoate 
• 1168135-11-2 2-(3-(benzo[d]thiazol-6-yl)-5-chloro-4-(cyclopropylmethoxy)phenyl)-4-methylpentanoic acid 
• 1168134-91-5 ethyl 2-(3-(benzo[d]thiazol-6-yl)-5-chloro-4-(cyclopropylmethoxy)phenyl)-4-methylpentanoate 
• 1168134-90-4 ethyl 2-(3-bromo-5-chloro-4-(cyclopropylmethoxy)phenyl)-4-methylpentanoate 
• 1168134-88-0 ethyl 2-(3-bromo-5-chloro-4-(cyclopropylmethoxy)phenyl)-4-methoxybutanoate 
• 1168120-61-3 1-(5-chloro-4'-isopropyl-6-(2,2,2-trifluoroethoxy)biphenyl-3-yl)cyclobutanecarboxylic acid 
• 1168134-75-5 ethyl 1-(5-chloro-4'-isopropyl-6-(2,2,2-trifluoroethoxy)biphenyl-3-yl)cyclobutanecarboxylate 
• 1168120-73-7 1-(5-chloro-4'-(methylthio)-6-(2,2,2-trifluoroethoxy)biphenyl-3-yl)cyclobutanecarboxylic acid 

Relevant articles and documents

L-Thyroxin and the Nonclassical Thyroid Hormone TETRAC Are Potent Activators of PPAR?

Thyroid hormones (THs) operate numerous physiological processes through modulation of the nuclear thyroid hormone receptors and several other proteins. We report direct activation of the nuclear peroxisome proliferator-activated receptor gamma (PPAR?) and retinoid X receptor (RXR) by classical and nonclassical THs as another molecular activity of THs. The T4 metabolite TETRAC was the most active TH on PPARγwith nanomolar potency and binding affinity. We demonstrate that TETRAC promotes PPAR?/RXR signaling in cell-free, cellular, and in vivo settings. Simultaneous activation of the heterodimer partners PPARγand RXR resulted in high dimer activation efficacy. Compared to fatty acids as known natural ligands of PPARγand RXR, TETRAC differs markedly in its molecular structure and the PPAR?-TETRAC complex revealed a distinctive binding mode of the TH. Our observations suggest a potential connection of TH and PPAR signaling through overlapping ligand recognition and may hold implications for TH and PPAR pharmacology.

BROMODOMAIN INHIBITORS

The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

TETRASUBSTITUTED BENZENES FOR TREATMENT OF EARLY ONSET ALZHEIMER'S DISEASE

Provided are compositions and methods for treating early onset familial Alzheimer's Disease. The compositions and methods can be used for improving one or more aspects of cognitive function in a patient suffering from early onset familial Alzheimer's Dise